CY1112120T1 - Ενα εμβολιο σκυλου για προστασια απο την ερλιχιωση - Google Patents

Ενα εμβολιο σκυλου για προστασια απο την ερλιχιωση

Info

Publication number
CY1112120T1
CY1112120T1 CY20111101194T CY111101194T CY1112120T1 CY 1112120 T1 CY1112120 T1 CY 1112120T1 CY 20111101194 T CY20111101194 T CY 20111101194T CY 111101194 T CY111101194 T CY 111101194T CY 1112120 T1 CY1112120 T1 CY 1112120T1
Authority
CY
Cyprus
Prior art keywords
protection against
agent
provides
against equipment
present
Prior art date
Application number
CY20111101194T
Other languages
English (en)
Inventor
Liangbiao Hu (George)
Thomas Jay Hess
Yu-Wei Chiang
Hsien-Jue CHU (Steve)
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CY1112120T1 publication Critical patent/CY1112120T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μία ασφαλή και αποτελεσματική εμβολιακή σύνθεση η οποία περιλαμβάνει: μία αποτελεσματική ανοσοποιητική ποσότητα μιας απενεργοποιημένης Ehrlichia canis βακτηρίνης˙ έναν φαρμακολογικά αποδεκτό φορέα˙ και μία ανοσογονικώς διεγερτική ποσότητα ενός ανοσοενισχυτικού συστήματος που αποτελείται ουσιαστικά από έναν παράγοντα που επάγει απόκριση αντισωμάτων και έναν παράγοντα που επάγει απόκριση κυτταροδιαμεσολαβούμενης ανοσίας. Η παρούσα εφεύρεση παρέχει επίσης μία μέθοδο για την πρόληψη ή βελτίωση της ερλιχίωσης σκύλου σε σκύλους.
CY20111101194T 2004-03-11 2011-12-02 Ενα εμβολιο σκυλου για προστασια απο την ερλιχιωση CY1112120T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55235004P 2004-03-11 2004-03-11
EP05735365A EP1723170B1 (en) 2004-03-11 2005-03-10 A canine vaccine for protection against ehrlichiosis

Publications (1)

Publication Number Publication Date
CY1112120T1 true CY1112120T1 (el) 2015-11-04

Family

ID=34965712

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101194T CY1112120T1 (el) 2004-03-11 2011-12-02 Ενα εμβολιο σκυλου για προστασια απο την ερλιχιωση

Country Status (22)

Country Link
US (2) US20050202046A1 (el)
EP (2) EP1723170B1 (el)
JP (1) JP2008500962A (el)
KR (1) KR20060129475A (el)
CN (1) CN1930185A (el)
AR (1) AR048030A1 (el)
AT (1) ATE530566T1 (el)
AU (1) AU2005222396A1 (el)
BR (1) BRPI0508655A (el)
CA (1) CA2558047A1 (el)
CO (1) CO5721012A2 (el)
CY (1) CY1112120T1 (el)
DK (1) DK1723170T3 (el)
ES (1) ES2374278T3 (el)
IL (1) IL177860A0 (el)
ME (1) ME01252B (el)
PL (1) PL1723170T3 (el)
PT (1) PT1723170E (el)
RS (1) RS52188B (el)
SI (1) SI1723170T1 (el)
WO (1) WO2005087803A1 (el)
ZA (1) ZA200607547B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115840A1 (en) * 1998-11-30 2002-08-22 Walker David H. Homologous 28-kilodaltion immunodominant protein genes of Ehrlichia canis and uses thereof
KR101192127B1 (ko) 2006-11-03 2012-10-17 쉐링-프라우 리미티드 개 라임병 백신
BRPI0809663B8 (pt) 2007-04-06 2021-05-25 Inviragen Inc composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado.
ES2618842T3 (es) 2007-09-11 2017-06-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vacuna atenuada para la erliquiosis
PT2190980T (pt) 2007-09-12 2016-10-07 Intervet Int Bv Métodos de cultura da espécies bacterianas da família das anaplasmatáceas
US9051557B2 (en) * 2007-09-12 2015-06-09 Intervet International B.V. Method for continuously culturing Ehrlichia canis
EP2045816A1 (en) * 2007-10-01 2009-04-08 Paul Scherrer Institut Fast readout method and swiched capacitor array circuitry for waveform digitizing
CN103200960B (zh) * 2010-07-02 2019-04-23 英特维特国际股份有限公司 针对犬埃利希体的疫苗和相关方法
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
KR102106762B1 (ko) 2012-10-11 2020-05-06 아박시스, 인크. 에를리히아 항체의 검출을 위한 펩티드, 장치, 그리고 방법
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
CA3070102A1 (en) * 2017-07-31 2019-02-07 Kansas State University Research Foundation Vaccines against tick-borne diseases
US11046734B2 (en) 2018-07-27 2021-06-29 Research Development Foundation Chimeric immunogenic polypeptides
CN114514238A (zh) * 2019-07-12 2022-05-17 研究发展基金会 埃立克体疫苗和免疫原性组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192679A (en) * 1990-05-03 1993-03-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Growing ehrlichia species in a continuous cell line
DE69132417T2 (de) * 1990-07-06 2001-05-23 American Home Prod Impfstoff gegen die Lyme-Krankheit
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
AU7208698A (en) * 1997-03-24 1998-10-20 Merial Canine ehrlichiosis immunogenic and diagnostic compositions and methods
US6043085A (en) 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
US6458942B1 (en) * 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
US6432649B1 (en) 2000-08-25 2002-08-13 The Ohio State University Research Foundation Methods for detecting Ehrlichia canis and Ehrlichia chaffeensis in vertebrate and invertebrate hosts
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant

Also Published As

Publication number Publication date
AR048030A1 (es) 2006-03-22
CA2558047A1 (en) 2005-09-22
SI1723170T1 (sl) 2012-01-31
PT1723170E (pt) 2012-01-10
US20050202046A1 (en) 2005-09-15
EP1723170B1 (en) 2011-10-26
BRPI0508655A (pt) 2007-08-14
CO5721012A2 (es) 2007-01-31
ES2374278T3 (es) 2012-02-15
EP2338903A1 (en) 2011-06-29
JP2008500962A (ja) 2008-01-17
ME01252B (me) 2013-06-20
US20060188524A1 (en) 2006-08-24
AU2005222396A1 (en) 2005-09-22
ATE530566T1 (de) 2011-11-15
DK1723170T3 (da) 2011-12-05
EP1723170A1 (en) 2006-11-22
US7635481B2 (en) 2009-12-22
PL1723170T3 (pl) 2012-03-30
CN1930185A (zh) 2007-03-14
KR20060129475A (ko) 2006-12-15
ZA200607547B (en) 2008-06-25
IL177860A0 (en) 2006-12-31
RS52188B (en) 2012-10-31
WO2005087803A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
CY1112120T1 (el) Ενα εμβολιο σκυλου για προστασια απο την ερλιχιωση
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
MXPA04000680A (es) Vacuna para virus west nile.
ATE511398T1 (de) Inaktiviertes poliovirus mischimpfstoff
ECSP034447A (es) Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis
NO20065480L (no) Vaksiner.
HK1083192A1 (en) West nile virus vaccine
TW200719910A (en) C. perfringens alpha toxoid vaccine
TW200731986A (en) Use of vaccines for the treatment/prevention of the transmission of pathogens
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
TW200733972A (en) Compositions and methods for the treatment of canine influenza virus disease
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
EA201001478A1 (ru) Вакцина
PH12017501853A1 (en) Bordetella pertussis immunogenic vaccine compositions
CL2013002219A1 (es) Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
WO2009044272A3 (en) Laser-based vaccine adjuvants
AR106978A1 (es) Vacunas felinas de núcleo híbrido
CY1113746T1 (el) Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ
UA97376C2 (uk) Вакцина
EA201200723A1 (ru) Антигены actinobacillus suis
PH12020550948A1 (en) Vaccines against hendra and nipah virus infection
DOP2009000068A (es) Vacuna que comprende un adyuvante de emulsión de aceite en agua
UA95646C2 (ru) Вакцина, которая включает адъювант на основе эмульсии масло-в-воде
AR111910A2 (es) Composición inmunogénica que comprende una formulación de adyuvante, composición de vacuna, procedimiento, usos, métodos